|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020616,
umls-concept:C0056552,
umls-concept:C0204727,
umls-concept:C0205409,
umls-concept:C0220781,
umls-concept:C0441655,
umls-concept:C0871161,
umls-concept:C1135800,
umls-concept:C1515655,
umls-concept:C1533691,
umls-concept:C1880355,
umls-concept:C1883254
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1998-4-16
|
|
pubmed:abstractText |
Using an ethnobotanical approach in combination with in vivo-guided fractionation as a means for lead discovery, cryptolepine was isolated as an antihyperglycemic component of Cryptolepis sanguinolenta. Two syntheses of cryptolepine, including an unambiguous synthesis, are reported. The hydroiodide, hydrochloride, and hydrotrifluoromethanesulfonate (hydrotriflate) salts of cryptolepine were synthesized, and a comparison of their spectral properties and their in vitro activities in a 3T3-L1 glucose transport assay is made. Cryptolepine and its salt forms lower blood glucose in rodent models of type II diabetes. While a number of bioactivities have been reported for cryptolepine, this is the first report that cryptolepine possesses antihyperglycemic properties.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:BiererD EDE,
pubmed-author:BrueningR CRC,
pubmed-author:CarlsonT JTJ,
pubmed-author:DubenkoL GLG,
pubmed-author:FortD MDM,
pubmed-author:GerberR ERE,
pubmed-author:HectorR FRF,
pubmed-author:ImbachP APA,
pubmed-author:JoladS DSD,
pubmed-author:KindS SSS,
pubmed-author:LitvakJJ,
pubmed-author:LumHH,
pubmed-author:MendezC DCD,
pubmed-author:NICC,
pubmed-author:NoamesiB KBK,
pubmed-author:ReesM WMW,
pubmed-author:WaldeckNN,
pubmed-author:ZhangPP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
12
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
894-901
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9526563-3T3 Cells,
pubmed-meshheading:9526563-Adipose Tissue,
pubmed-meshheading:9526563-Alkaloids,
pubmed-meshheading:9526563-Animals,
pubmed-meshheading:9526563-Blood Glucose,
pubmed-meshheading:9526563-Body Weight,
pubmed-meshheading:9526563-Diabetes Mellitus, Experimental,
pubmed-meshheading:9526563-Eating,
pubmed-meshheading:9526563-Fructose,
pubmed-meshheading:9526563-Glucose,
pubmed-meshheading:9526563-Hypoglycemic Agents,
pubmed-meshheading:9526563-Indole Alkaloids,
pubmed-meshheading:9526563-Indoles,
pubmed-meshheading:9526563-Male,
pubmed-meshheading:9526563-Mice,
pubmed-meshheading:9526563-Mice, Obese,
pubmed-meshheading:9526563-Plant Extracts,
pubmed-meshheading:9526563-Quinolines,
pubmed-meshheading:9526563-Rats,
pubmed-meshheading:9526563-Rats, Sprague-Dawley
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
|
|
pubmed:affiliation |
Shaman Pharmaceuticals, Inc., South San Francisco, California 94080, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro
|
